RxDoctor Payments Data

Abdul Sheikh, MD

Interventional Cardiology · Hiram, GANPI 1518925981

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $38,500 of the $56,533 with a category attached, or 68.1%. Boston Scientific accounts for 92.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $27,501 and has fallen 85.2% since, to $4,060 in 2025.

$56,533in general payments, 2019–2025

Across 236 payments — averaging $239.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$52K
  • Medtronic$987
  • Novartis$388
  • Abiomed$334
  • W. L. Gore & Associates, Inc.$313
  • Abbott$308
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$2,5004%
  • Speaking & faculty fees$38,50068%
  • Grants$1100%
  • Travel & lodging$9,13716%
  • Food & beverage$6,28711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,533 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$222,557
Medicare patients
1,228
Services billed
4,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban604$689,656
XareltoRivaroxaban160$176,516
JardianceEmpagliflozin64$73,055
EntrestoSacubitril/Valsartan61$69,466
Repatha SureclickEvolocumab81$53,894
FarxigaDapagliflozin Propanediol29$38,207
Repatha SyringeEvolocumab18$16,109
Praluent PenAlirocumab16$11,651
Ranolazine ErRanolazine129$11,451
Atorvastatin Calcium622$5,515
Metoprolol Succinate394$4,769
Valsartan122$4,102
ClopidogrelClopidogrel Bisulfate433$3,846
Isosorbide Mononitrate ErIsosorbide Mononitrate261$3,698
Diltiazem 24hr Er (Cd)Diltiazem Hcl92$3,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$689,656604 claims
Johnson & JohnsonXarelto$154$176,516160 claims
Boehringer IngelheimJardiance$60$73,05564 claims
NovartisEntresto$388$69,46661 claims
AstraZenecaFarxiga$115$38,20729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Hiram

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →